Advances in silica based nanoparticles for targeted cancer therapy

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 2, 2016, Pages 317-332

  Yang, Yannan ^a   Yu, Chengzhong ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Active targeting; Cancer therapy; Magnetic field directed targeting; Passive targeting; Silica nanoparticles

Indexed keywords

DISEASES; MAGNETIC FIELDS; NANOPARTICLES; ONCOLOGY; SILICA; TUMORS;

ACTIVE TARGETING; CANCER THERAPY; MESOPOROUS SILICA NANOPARTICLES; PASSIVE TARGETING; PHYSIO-CHEMICAL PROPERTIES; SILICA NANOPARTICLES; TARGETED CANCER THERAPY; TARGETED DRUG DELIVERY;

NANOMAGNETICS;

ANTINEOPLASTIC AGENT; MAGNETIC NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLE; SILICA NANOPARTICLE; DRUG CARRIER; NANOPARTICLE; SILICON DIOXIDE;

ACTIVE TARGETING; CANCER THERAPY; CELL NUCLEUS; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; HUMAN; MAGNETIC FIELD; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PASSIVE TARGETING; REVIEW; SURFACE CHARGE; TUMOR CELL; TUMOR VASCULARIZATION; ANIMAL; CHEMISTRY; MAGNETISM; NEOPLASMS; PATHOLOGY; PROCEDURES; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MAGNETIC FIELDS; MAGNETICS; NANOPARTICLES; NEOPLASMS; SILICON DIOXIDE;

EID: 84954288779     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.10.018     Document Type: Review

References (190)

1. LaVan D.A., McGuire T., Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003, 21(10):1184-1191.
2. Langer R. New methods of drug delivery. Science 1990, 249(4976):1527-1533.
3. Shi J.J., Xiao Z.Y., Kamaly N., Farokhzad O.C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011, 44(10):1123-1134.
4. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across lamellae of swollen phospholipids. J Mol Biol 1965, 13(1):238. [-&].
5. Barreto J.A., O'Malley W., Kubeil M., Graham B., Stephan H., Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater 2011, 23(12):H18-H40.
6. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83(5):761-769.
7. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B 2010, 75(1):1-18.
8. Wang X., Wang Y.Q., Chen Z., Shin D.M. Advances of cancer therapy by nanotechnology. Cancer Res Treat 2009, 41(1):1-11.
9. Cegnar M., Kristl J., Kos J. Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Expert Opin Biol Ther 2005, 5(12):1557-1569.
10. Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 2011, 40(3):1647-1671.
11. Mahmoudi M., Sant S., Wang B., Laurent S., Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011, 63(1-2):24-46.
12. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013, 12(11):967-977.
13. Vallet-Regi M., Ramila A., del Real R.P., Perez-Pariente J. A new property of MCM-41: drug delivery system. Chem Mater 2001, 13(2):308-311.
14. Wu S.H., Mou C.Y., Lin H.P. Synthesis of mesoporous silica nanoparticles. Chem Soc Rev 2013, 42(9):3862-3875.
15. Li Z.X., Barnes J.C., Bosoy A., Stoddart J.F., Zink J.I. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev 2012, 41(7):2590-2605.
16. Tang F.Q., Li L.L., Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 2012, 24(12):1504-1534.
17. Rosenholm J.M., Sahlgren C., Linden M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles-opportunities & challenges. Nanoscale 2010, 2(10):1870-1883.
18. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy-mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res 1986, 46(12):6387-6392.
19. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7(11):653-664.
20. Baeza A., Colilla M., Vallet-Regi M. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery. Expert Opin Drug Deliv 2015, 12(2):319-337.
21. Han N., Zhao Q.F., Wan L., Wang Y., Gao Y.K., Wang P., et al. Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance. ACS Appl Mater Interfaces 2015, 7(5):3342-3351.
22. Ma M., Zheng S.G., Chen H.R., Yao M.H., Zhang K., Jia X.Q., et al. A combined "RAFT" and "Graft From" polymerization strategy for surface modification of mesoporous silica nanoparticles: towards enhanced tumor accumulation and cancer therapy efficacy. J Mater Chem B 2014, 2(35):5828-5836.
23. Kim H.L., Lee S.B., Jeong H.J., Kim D.W. Enhanced tumor targetability of PEGylated mesoporous silica nanoparticles on in vivo optical imaging according to their size. RSC Adv 2014, 4(59):31318-31322.
24. Fan W.P., Shen B., Bu W.B., Chen F., He Q.J., Zhao K.L., et al. A smart upconversion-based mesoporous silica nanotheranostic system for synergetic chemo-/radio-/photodynamic therapy and simultaneous MR/UCL imaging. Biomaterials 2014, 35(32):8992-9002.
25. Kumar R., Roy I., Ohulchanskky T.Y., Vathy L.A., Bergey E.J., Sajjad M., et al. In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. Acs Nano 2010, 4(2):699-708.
26. Feng W., Nie W., He C.L., Zhou X.J., Chen L., Qiu K.X., et al. Effect of pH-responsive alginate/chitosan multilayers coating on delivery efficiency, cellular uptake and biodistribution of mesoporous silica nanoparticles based nanocarriers. ACS Appl Mater Interfaces 2014, 6(11):8447-8460.
27. Lu J., Liong M., Li Z.X., Zink J.I., Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 2010, 6(16):1794-1805.
28. Liu T.L., Li L.L., Fu C.H., Liu H.Y., Chen D., Tang F.Q. Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles. Biomaterials 2012, 33(7):2399-2407.
29. Huang X.L., Zhuang J., Teng X., Li L.L., Chen D., Yan X.Y., et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials 2010, 31(24):6142-6153.
30. Lu J., Li Z.X., Zink J.I., Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomed Nanotechnol 2012, 8(2):212-220.
31. Chen Y., Chen H.R., Shi J.L. In vivo Bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater 2013, 25(23):3144-3176.
32. Yu M.X., Zheng J. Clearance pathways and tumor targeting of imaging nanoparticles. ACS Nano 2015, 9(7):6655-6674.
33. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7(9):771-782.
34. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of anticancer agents and polymers-advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992, 3(5):351-362.
35. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65(1-2):271-284.
36. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 2011, 63(3):161-169.
37. He Q.J., Zhang Z.W., Gao F., Li Y.P., Shi J.L. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 2011, 7(2):271-280.
38. O'Neal D.P., Hirsch L.R., Halas N.J., Payne J.D., West J.L. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett 2004, 209(2):171-176.
39. Lu F., Wu S.H., Hung Y., Mou C.Y. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small 2009, 5(12):1408-1413.
40. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6(4):662-668.
41. Osaki F., Kanamori T., Sando S., Sera T., Aoyama Y. A quantum dot conjugated sugar ball and its cellular uptake on the size effects of endocytosis in the subviral region. J Am Chem Soc 2004, 126(21):6520-6521.
42. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9(8):615-627.
43. Geng Y., Dalhaimer P., Cai S.S., Tsai R., Tewari M., Minko T., et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007, 2(4):249-255.
44. Lee S.Y., Ferrari M., Decuzzi P. Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology 2009, 20(49).
45. Gao H.J., Shi W.D., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A 2005, 102(27):9469-9474.
46. Yang K., Ma Y.Q. Computer simulation of the translocation of nanoparticles with different shapes across a lipid bilayer. Nat Nanotechnol 2010, 5(8):579-583.
47. Trewyn B.G., Nieweg J.A., Zhao Y., Lin V.S.Y. Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane, penetration. Chem Eng J 2008, 137(1):23-29.
48. Huang X.L., Teng X., Chen D., Tang F.Q., He J.Q. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 2010, 31(3):438-448.
49. Meng H., Yang S., Li Z.X., Xia T., Chen J., Ji Z.X., et al. Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano 2011, 5(6):4434-4447.
50. Chauhan V.P., Popovic Z., Chen O., Cui J., Fukumura D., Bawendi M.G., et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl 2011, 50(48):11417-11420.
51. Decuzzi P., Godin B., Tanaka T., Lee S.Y., Chiappini C., Liu X., et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release 2010, 141(3):320-327.
52. Huang X.L., Li L.L., Liu T.L., Hao N.J., Liu H.Y., Chen D., et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 2011, 5(7):5390-5399.
53. Chithrani B.D., Chan W.C.W. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007, 7(6):1542-1550.
54. Florez L., Herrmann C., Cramer J.M., Hauser C.P., Koynov K., Landfester K., et al. How shape influences uptake: interactions of anisotropic polymer nanoparticles and human mesenchymal stem cells. Small 2012, 8(14):2222-2230.
55. Zhang Y., Tekobo S., Tu Y., Zhou Q.F., Jin X.L., Dergunov S.A., et al. Permission to enter cell by shape: nanodisk vs nanosphere. ACS Appl Mater Interfaces 2012, 4(8):4099-4105.
56. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M.V., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8(7):543-557.
57. Zhang Z.P., Feng S.S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27(2):262-270.
58. Slowing I.I., Wu C.W., Vivero-Escoto J.L., Lin V.S.Y. Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. Small 2009, 5(1):57-62.
59. Teng Z.G., Wang S.J., Su X.D., Chen G.T., Liu Y., Luo Z.M., et al. Facile synthesis of yolk-shell structured inorganic-organic hybrid spheres with ordered radial mesochannels. Adv Mater 2014, 26(22):3741-3747.
60. Urata C., Yamada H., Wakabayashi R., Aoyama Y., Hirosawa S., Arai S., et al. Aqueous colloidal mesoporous nanoparticles with ethenylene-bridged silsesquioxane frameworks. J Am Chem Soc 2011, 133(21):8102-8105.
61. Chen Y., Xu P.F., Chen H.R., Li Y.S., Bu W.B., Shu Z., et al. Colloidal HPMO nanoparticles: silica-etching chemistry tailoring, topological transformation, and nano-biomedical applications. Adv Mater 2013, 25(22):3100-3105.
62. Del Pino P., Pelaz B., Zhang Q., Maffre P., Nienhaus G.U., Parak W.J. Protein corona formation around nanoparticles-from the past to the future. Mater Horiz 2014, 1(3):301-313.
63. Meng H., Xue M., Xia T., Ji Z.X., Tarn D.Y., Zink J.I., et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 2011, 5(5):4131-4144.
64. Cauda V., Argyo C., Bein T. Impact of different PEGylation patterns on the long-term bio-stability of colloidal mesoporous silica nanoparticles. J Mater Chem 2010, 20(39):8693-8699.
65. Karakoti A.S., Das S., Thevuthasan S., Seal S. PEGylated inorganic nanoparticles. Angew Chem Int Ed Engl 2011, 50(9):1980-1994.
66. He Q.J., Zhang J.M., Shi J.L., Zhu Z.Y., Zhang L.X., Bu W.B., et al. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses. Biomaterials 2010, 31(6):1085-1092.
67. Cauda V., Schlossbauer A., Bein T. Bio-degradation study of colloidal mesoporous silica nanoparticles: effect of surface functionalization with organo-silanes and poly(ethylene glycol). Microporous Mesoporous Mater 2010, 132(1-2):60-71.
68. Otsuka H., Nagasaki Y., Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003, 55(3):403-419.
69. Lin Y.S., Haynes C.L. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J Am Chem Soc 2010, 132(13):4834-4842.
70. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10(21):1451-1458.
71. Hatakeyama H., Akita H., Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 2011, 63(3):152-160.
72. Ostuni E., Chapman R.G., Holmlin R.E., Takayama S., Whitesides G.M. A survey of structure-property relationships of surfaces that resist the adsorption of protein. Langmuir 2001, 17(18):5605-5620.
73. Shen M.C., Martinson L., Wagner M.S., Castner D.G., Ratner B.D., Horbett T.A. PEO-like plasma polymerized tetraglyme surface interactions with leukocytes and proteins: in vitro and in vivo studies. J Biomater Sci Polym Ed 2002, 13(4):367-390.
74. Luk Y.Y., Kato M., Mrksich M. Self-assembled monolayers of alkanethiolates presenting mannitol groups are inert to protein adsorption and cell attachment. Langmuir 2000, 16(24):9604-9608.
75. Leckband D., Sheth S., Halperin A. Grafted poly(ethylene oxide) brushes as nonfouling surface coatings. J Biomater Sci Polym Ed 1999, 10(10):1125-1147.
76. Dams E.T.M., Laverman P., Oyen W.J.G., Storm G., Scherphof G.L., Van der Meer J.W.M., et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 2000, 292(3):1071-1079.
77. Laverman P., Carstens M.G., Boerman O.C., Dams E.T.M., Oyen W.J.G., Van Rooijen N., et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 2001, 298(2):607-612.
78. Laverman P., Boerman O.C., Oyen W.J.G., Corstens F.H.M., Storm G. In vivo applications of PEG liposomes: unexpected observations. Crit Rev Ther Drug 2001, 18(6):551-566.
79. Ishida T., Maeda R., Ichihara M., Mukai Y., Motoki Y., Manabe Y., et al. The accelerated clearance on repeated injection of PEGylated liposomes in rats: laboratory and histopathological study. Cell Mol Biol Lett 2002, 7(2):286.
80. Ishida T., Maeda R., Ichihara M., Irimura K., Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release 2003, 88(1):35-42.
81. Ishida T., Masuda K., Ichikawa T., Ichihara M., Irimura K., Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm 2003, 255(1-2):167-174.
82. Ishida T., Harada M., Wang X.Y., Ichihara M., Irimura K., Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release 2005, 105(3):305-317.
83. Wang X.Y., Ishida T., Ichihara M., Kiwada H. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J Control Release 2005, 104(1):91-102.
84. Ishida T., Ichihara M., Wang X., Yamamoto K., Kimura J., Majima E., et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 2006, 112(1):15-25.
85. Chen S.F., Zheng J., Li L.Y., Jiang S.Y. Strong resistance of phosphorylcholine self-assembled monolayers to protein adsorption: insights into nonfouling properties of zwitterionic materials. J Am Chem Soc 2005, 127(41):14473-14478.
86. Chen S.F., Liu L.Y., Jiang S.Y. Strong resistance of oligo(phosphorylcholine) self-assembled monolayers to protein adsorption. Langmuir 2006, 22(6):2418-2421.
87. Jia G.W., Cao Z.Q., Xue H., Xu Y.S., Jiang S.Y. Novel zwitterionic-polymer-coated silica nanoparticles. Langmuir 2009, 25(5):3196-3199.
88. Rosen J.E., Gu F.X. Surface functionalization of silica nanoparticles with cysteine: a Low-fouling zwitterionic surface. Langmuir 2011, 27(17):10507-10513.
89. Zhu Y.H., Sundaram H.S., Liu S.J., Zhang L., Xu X.W., Yu Q.M., et al. A robust graft-to strategy to form multifunctional and stealth zwitterionic polymer-coated mesoporous silica nanoparticles. Biomacromolecules 2014, 15(5):1845-1851.
90. Liu J.W., Stace-Naughton A., Jiang X.M., Brinker C.J. Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J Am Chem Soc 2009, 131(4):1354-1355.
91. Wang L.S., Wu L.C., Lu S.Y., Chang L.L., Teng I.T., Yang C.M., et al. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. ACS Nano 2010, 4(8):4371-4379.
92. van Schooneveld M.M., Vucic E., Koole R., Zhou Y., Stocks J., Cormode D.P., et al. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett 2008, 8(8):2517-2525.
93. Yang Y., Song W.X., Wang A.H., Zhu P.L., Fei J.B., Li J.B. Lipid coated mesoporous silica nanoparticles as photosensitive drug carriers. Phys Chem Chem Phys 2010, 12(17):4418-4422.
94. Ashley C.E., Carnes E.C., Phillips G.K., Padilla D., Durfee P.N., Brown P.A., et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers (vol 10, pg 389, 2011). Nat Mater 2011, 10(6):476.
95. Fleck C.C., Netz R.R. Electrostatic colloid-membrane binding. Europhys Lett 2004, 67(2):314-320.
96. Bertrand N., Wu J., Xu X.Y., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014, 66:2-25.
97. Yuan Y.Y., Mao C.Q., Du X.J., Du J.Z., Wang F., Wang J. Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor. Adv Mater 2012, 24(40):5476-5480.
98. Albanese A., Tang P.S., Chan W.C.W. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012, 14:1-16.
99. Verma A., Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6(1):12-21.
100. Goff S.P., Berg P. Construction of hybrid viruses containing Sv40 and gamma phage DNA segments and their propagation in cultured monkey cells. Cell 1976, 9(4):695-705.
101. Niu Y.T., Yu M.H., Hartono S.B., Yang J., Xu H.Y., Zhang H.W., et al. Nanoparticles mimicking viral surface topography for enhanced cellular delivery. Adv Mater 2013, 25(43):6233-6237.
102. Xu C., Niu Y.T., Popat A., Jambhrunkar S., Karmakar S., Yu C.Z. Rod-like mesoporous silica nanoparticles with rough surfaces for enhanced cellular delivery. J Mater Chem B 2014, 2(3):253-256.
103. Agueros M., Areses P., Campanero M.A., Salman H., Quincoces G., Penuelas I., et al. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur J Pharm Sci 2009, 37(3-4):231-240.
104. Hoek E.M.V., Agarwal G.K. Extended DLVO interactions between spherical particles and rough surfaces. J Colloid Interface Sci 2006, 298(1):50-58.
105. Mitragotri S., Lahann J. Physical approaches to biomaterial design. Nat Mater 2009, 8(1):15-23.
106. Merkel T.J., Jones S.W., Herlihy K.P., Kersey F.R., Shields A.R., Napier M., et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci U S A 2011, 108(2):586-591.
107. Merkel T.J., Chen K., Jones S.W., Pandya A.A., Tian S.M., Napier M.E., et al. The effect of particle size on the biodistribution of low-modulus hydrogel PRINT particles. J Control Release 2012, 162(1):37-44.
108. Sun T.M., Zhang Y.S., Pang B., Hyun D.C., Yang M.X., Xia Y.N. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl 2014, 53(46):12320-12364.
109. Leserman L.D., Barbet J., Kourilsky F., Weinstein J.N. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein-a. Nature 1980, 288(5791):602-604.
110. Wang X.Q., Li S.X., Shi Y.J., Chuan X.X., Li J., Zhong T., et al. The development of site-specific drug delivery nanocarriers based on receptor mediation. J Control Release 2014, 193:139-153.
111. Kamaly N., Xiao Z.Y., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41(7):2971-3010.
112. Slowing I., Trewyn B.G., Lin V.S.Y. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J Am Chem Soc 2006, 128(46):14792-14793.
113. Rosenholm J.M., Meinander A., Peuhu E., Niemi R., Eriksson J.E., Sahlgren C., et al. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano 2009, 3(1):197-206.
114. Liong M., Lu J., Kovochich M., Xia T., Ruehm S.G., Nel A.E., et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008, 2(5):889-896.
115. Rosenholm J.M., Peuhu E., Bate-Eya L.T., Eriksson J.E., Sahlgren C., Linden M. Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. Small 2010, 6(11):1234-1241.
116. Yu M.H., Jambhrunkar S., Thorn P., Chen J.Z., Gu W.Y., Yu C.Z. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale 2013, 5(1):178-183.
117. Luo Z., Cai K.Y., Hu Y., Zhao L., Liu P., Duan L., et al. Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery. Angew Chem Int Ed Engl 2011, 50(3):640-643.
118. Liu J.W., Cao Z.H., Lu Y. Functional nucleic acid sensors. Chem Rev 2009, 109(5):1948-1998.
119. Pestourie C., Tavitian B., Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie 2005, 87(9-10):921-930.
120. Farokhzad O.C., Cheng J.J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006, 103(16):6315-6320.
121. Farokhzad O.C., Jon S.Y., Khademhosseini A., Tran T.N.T., LaVan D.A., Langer R. Nanopartide-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004, 64(21):7668-7672.
122. Zhang L.F., Radovic-Moreno A.F., Alexis F., Gu F.X., Basto P.A., Bagalkot V., et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007, 2(9):1268-1271.
123. Huang Y.F., Shangguan D.H., Liu H.P., Phillips J.A., Zhang X.L., Chen Y., et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 2009, 10(5):862-868.
124. Wu Y.R., Sefah K., Liu H.P., Wang R.W., Tan W.H. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci U S A 2010, 107(1):5-10.
125. Bagalkot V., Farokhzad O.C., Langer R., Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 2006, 45(48):8149-8152.
126. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006, 24(8):1005-1015.
127. Gu F., Zhang L., Teply B.A., Mann N., Wang A., Radovic-Moreno A.F., et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A 2008, 105(7):2586-2591.
128. Zhu C.L., Song X.Y., Zhou W.H., Yang H.H., Wen Y.H., Wang X.R. An efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugates. J Mater Chem 2009, 19(41):7765-7770.
129. Gao L., Cui Y., He Q., Yang Y., Fei J.B., Li J.B. Selective recognition of Co-assembled thrombin aptamer and docetaxel on mesoporous silica nanoparticles against tumor cell proliferation. Chem Eur J 2011, 17(47):13170-13174.
130. Li L.L., Yin Q., Cheng J.J., Lu Y. Polyvalent mesoporous silica nanoparticle-aptamer bioconjugates target breast cancer cells. Adv Healthc Mater 2012, 1(5):567-572.
131. Zhang P.H., Cheng F.F., Zhou R., Cao J.T., Li J.J., Burda C., et al. DNA-hybrid-gated multifunctional mesoporous silica nanocarriers for dual-targeted and microRNA-responsive controlled drug delivery**. Angew Chem Int Ed Engl 2014, 53(9):2371-2375.
132. Liu C.H., Zheng J., Deng L., Ma C., Li J.S., Li Y.H., et al. Targeted intracellular controlled drug delivery and tumor therapy through in situ forming Ag nanogates on mesoporous silica nanocontainers. ACS Appl Mater Interfaces 2015, 7(22):11930-11938.
133. Ferris D.P., Lu J., Gothard C., Yanes R., Thomas C.R., Olsen J.C., et al. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small 2011, 7(13):1816-1826.
134. Deng Z.W., Zhen Z.P., Hu X.X., Wu S.L., Xu Z.S., Chu P.K. Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy. Biomaterials 2011, 32(21):4976-4986.
135. Tsai C.P., Chen C.Y., Hung Y., Chang F.H., Mou C.Y. Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. J Mater Chem 2009, 19(32):5737-5743.
136. Cheng K., Blumen S.R., MacPherson M.B., Steinbacher J.L., Mossman B.T., Landry C.C. Enhanced uptake of porous silica microparticles by bifunctional surface modification with a targeting antibody and a biocompatible polymer. ACS Appl Mater Interfaces 2010, 2(9):2489-2495.
137. Milgroom A., Intrator M., Madhavan K., Mazzaro L., Shandas R., Liu B.L., et al. Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. Colloids Surf B 2014, 116:652-657.
138. Kwon I.K., Lee S.C., Han B., Park K. Analysis on the current status of targeted drug delivery to tumors. J Control Release 2012, 164(2):108-114.
139. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3(1):16-20.
140. Pirollo K.F., Chang E.H. Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol 2008, 26(10):552-558.
141. Grantab R., Sivananthan S., Tannock I.F. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 2006, 66(2):1033-1039.
142. Florence A.T. Pharmaceutical nanotechnology: more than size ten topics for research. Int J Pharm 2007, 339(1-2):1-2.
143. Yoo H.S., Park T.G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 2004, 96(2):273-283.
144. Laginha K., Mumbengegwi D., Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. BBA Biomembranes 2005, 1711(1):25-32.
145. Salvati A., Pitek A.S., Monopoli M.P., Prapainop K., Bombelli F.B., Hristov D.R., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013, 8(2):137-143.
146. Shinoda T., Takagi A., Maeda A., Kagatani S., Konno Y., Hashida M. In vivo fate of folate-BSA in non-tumor- and tumor-bearing mice. J Pharm Sci 1998, 87(12):1521-1526.
147. Neri D., Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005, 5(6):436-446.
148. Shi S.X., Yang K., Hong H., Valdovinos H.F., Nayak T.R., Zhang Y., et al. Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials 2013, 34(12):3002-3009.
149. Hong H., Yang K., Zhang Y., Engle J.W., Feng L.Z., Yang Y.A., et al. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano 2012, 6(3):2361-2370.
150. Xiao Y.L., Hong H., Javadi A., Engle J.W., Xu W.J., Yang Y.A., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33(11):3071-3082.
151. Seon B.K., Haba A., Matsuno F., Takahashi N., Tsujie M., She X.W., et al. Endoglin-targeted cancer therapy. Curr Drug Deliv 2011, 8(1):135-143.
152. WOGLOM W.H. A critique of tumor resistance. J Cancer Res 1923, 7:283-309.
153. Burrows F.J., Thorpe P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A 1993, 90(19):8996-9000.
154. Cai W.B., Shin D.W., Chen K., Gheysens O., Cao Q.Z., Wang S.X., et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006, 6(4):669-676.
155. Liu Z., Cai W.B., He L.N., Nakayama N., Chen K., Sun X.M., et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007, 2(1):47-52.
156. Chen F., Hong H., Zhang Y., Valdovinos H.F., Shi S.X., Kwon G.S., et al. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radio labeled mesoporous silica nanoparticles. ACS Nano 2013, 7(10):9027-9039.
157. Chen H.M., Zhen Z.P., Tang W., Todd T., Chuang Y.J., Wang L.C., et al. Label-free luminescent mesoporous silica nanoparticles for imaging and drug delivery. Theranostics 2013, 3(9):650-657.
158. Chen F., Hong H., Goel S., Graves S.A., Orbay H., Ehlerding E.B., et al. In vivo tumor vasculature targeting of CuS@MSN based theranostic nanomedicine. ACS Nano 2015, 9(4):3926-3934.
159. Chen F., Nayak T.R., Goel S., Valdovinos H.F., Hong H., Theuer C.P., et al. In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol Pharm 2014, 11(11):4007-4014.
160. Chakravarty R., Goel S., Hong H., Chen F., Valdovinos H.F., Hernandez R., et al. Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery. Nanomedicine 2015, 10(8):1233-1246.
161. Goel S., Chen F., Hong H., Valdovinos H.F., Hernandez R., Shi S.X., et al. VEGF(121)-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. ACS Appl Mater Interfaces 2014, 6(23):21677-21685.
162. Yang H., Zhao F.L., Li Y., Xu M.M., Li L., Wu C.H., et al. VCAM-1-targeted core/shell nanoparticles for selective adhesion and delivery to endothelial cells with lipopolysaccharide-induced inflammation under shear flow and cellular magnetic resonance imaging in vitro. Int J Nanomedicine 2013, 8. 10.2147/IJN.S44997.
163. Chen F., Hong H., Shi S.X., Goel S., Valdovinos H.F., Hernandez R., et al. Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep 2014, 4. 10.1038/srep05080.
164. Mizutani H., Tada-Oikawa S., Hiraku Y., Kojima M., Kawanishi S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 2005, 76(13):1439-1453.
165. Austin L.A., Kang B., Yen C.W., El-Sayed M.A. Nuclear targeted silver nanospheres perturb the cancer cell cycle differently than those of nanogold. Bioconjug Chem 2011, 22(11):2324-2331.
166. Austin L.A., Kang B., Yen C.W., El-Sayed M.A. Plasmonic imaging of human oral cancer cell communities during programmed cell death by nuclear-targeting silver nanoparticles. J Am Chem Soc 2011, 133(44):17594-17597.
167. Chen F.Q., Gerion D. Fluorescent CdSe/ZnS nanocrystal-peptide conjugates for long-term, nontoxic imaging and nuclear targeting in living cells. Nano Lett 2004, 4(10):1827-1832.
168. Xu C.J., Xie J., Kohler N., Walsh E.G., Chin Y.E., Sun S.H. Monodisperse magnetite nanoparticles coupled with nuclear localization signal peptide for cell-nucleus targeting. Chem Asian J 2008, 3(3):548-552.
169. Tkachenko A.G., Xie H., Coleman D., Glomm W., Ryan J., Anderson M.F., et al. Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. J Am Chem Soc 2003, 125(16):4700-4701.
170. Lin S.Y., Chen N.T., Sun S.P., Chang J.C., Wang Y.C., Yang C.S., et al. The protease-mediated nucleus shuttles of subnanometer gold quantum dots for real-time monitoring of apoptotic cell death. J Am Chem Soc 2010, 132(24):8309-8315.
171. de la Fuente J.M., Berry C.C. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug Chem 2005, 16(5):1176-1180.
172. Pan L.M., He Q.J., Liu J.N., Chen Y., Ma M., Zhang L.L., et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J Am Chem Soc 2012, 134(13):5722-5725.
173. Pan L.M., Liu J.A., He Q.J., Wang L.J., Shi J.L. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials 2013, 34(11):2719-2730.
174. Wu M.Y., Meng Q.S., Chen Y., Du Y.Y., Zhang L.X., Li Y.P., et al. Large-pore ultrasmall mesoporous organosilica nanoparticles: micelle/precursor co-templating assembly and nuclear-targeted gene delivery. Adv Mater 2015, 27(2):215-222.
175. Li Z.H., Dong K., Huang S., Ju E.G., Liu Z., Yin M.L., et al. A smart nanoassembly for multistage targeted drug delivery and magnetic resonance imaging. Adv Funct Mater 2014, 24(23):3612-3620.
176. Pan L.M., Liu J.N., He Q.J., Shi J.L. MSN-mediated sequential vascular-to-cell nuclear-targeted drug delivery for efficient tumor regression. Adv Mater 2014, 26(39):6742-6748.
177. Zhao W.R., Chen H.R., Li Y.S., Li L., Lang M.D., Shi J.L. Uniform rattle-type hollow magnetic mesoporous spheres as drug delivery carriers and their sustained-release property. Adv Funct Mater 2008, 18(18):2780-2788.
178. Wu H.X., Liu G., Zhang S.J., Shi J.L., Zhang L.X., Chen Y., et al. Biocompatibility, MR imaging and targeted drug delivery of a rattle-type magnetic mesoporous silica nanosphere system conjugated with PEG and cancer-cell-specific ligands. J Mater Chem 2011, 21(9):3037-3045.
179. Zhang F., Braun G.B., Pallaoro A., Zhang Y.C., Shi Y.F., Cui D.X., et al. Mesoporous multifunctional upconversion luminescent and magnetic "nanorattle" materials for targeted chemotherapy. Nano Lett 2012, 12(1):61-67.
180. Croissant J., Cattoen X., Man M.W.C., Gallud A., Raehm L., Trens P., et al. Biodegradable ethylene-bis(propyl)disulfide-based periodic mesoporous organosilica nanorods and nanospheres for efficient in-vitro drug delivery. Adv Mater 2014, 26(35):6174-6180.
181. Hao X., Hu X., Zhang C., Chen S., Li Z., Yang X., et al. Hybrid mesoporous silica-based drug carrier nanostructures with improved degradability by hydroxyapatite. ACS Nano 2015, 9(10):9614-9625.
182. Namdee K., Thompson A.J., Charoenphol P., Eniola-Adefeso O. Margination propensity of vascular-targeted spheres from blood flow in a microfluidic model of human microvessels. Langmuir 2013, 29(8):2530-2535.
183. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K.L., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66(13):6732-6740.
184. Huang X.H., Peng X.H., Wang Y.Q., Wang Y.X., Shin D.M., El-Sayed M.A., et al. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano 2010, 4(10):5887-5896.
185. Yu M.H., Karmakar S., Yang J., Zhang H.W., Yang Y.N., Thorn P., et al. Facile synthesis of ultra-small hybrid silica spheres for enhanced penetration in 3D glioma spheroids. Chem Commun 2014, 50(13):1527-1529.
186. Huh D., Matthews B.D., Mammoto A., Montoya-Zavala M., Hsin H.Y., Ingber D.E. Reconstituting organ-level lung functions on a chip. Science 2010, 328(5986):1662-1668.
187. Huh D., Hamilton G.A., Ingber D.E. From 3D cell culture to organs-on-chips. Trends Cell Biol 2011, 21(12):745-754.
188. Huh D., Torisawa Y.S., Hamilton G.A., Kim H.J., Ingber D.E. Microengineered physiological biomimicry: organs-on-chips. Lab Chip 2012, 12(12):2156-2164.
189. Sung J.H., Shuler M.L. A micro cell culture analog (mu CCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip 2009, 9(10):1385-1394.
190. Sung J.H., Esch M.B., Shuler M.L. Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling. Expert Opin Drug Metab Toxicol 2010, 6(9):1063-1081.